The American Heart Association and the American College of Cardiology's new guidelines for 2025 emphasize early intervention.

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s | ...

The small study followed patients for six months and found that 54 percent experienced a reduction in their symptoms after taking a GLP-1RA. Most of the patients had type 2 diabetes and the median BMI ...